Scrotal Edema Associated with the Use of Dasatinib in Patients with Chronic Myeloid Leukemia
| Autor: | Nitin Jain, Hagop M. Kantarjian, Pat Ault, Jorge E. Cortes |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.drug_class Pleural effusion Peripheral edema Myeloid leukemia Imatinib General Medicine medicine.disease Gastroenterology Tyrosine-kinase inhibitor Dasatinib hemic and lymphatic diseases Internal medicine Immunology medicine In patient medicine.symptom business Complication medicine.drug |
| Zdroj: | Clinical Leukemia. 1:357-358 |
| ISSN: | 1931-6925 |
| DOI: | 10.3816/clk.2007.n.030 |
| Popis: | Dasatinib is a new tyrosine kinase inhibitor which is approved by the FDA for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. Dasatinib can cause fluid retention in some patients, leading to peripheral edema and pleural effusion. Herein, we report 2 patients with chronic phase CML who developed significant scrotal and penile edema while on treatment with dasatinib. In both patients, transient dasatinib interruption and use of diuretics helped alleviate the symptoms. Both patients had the dose schedule of dasatinib switched to once daily from twice daily. Scrotal and penile edemas are unusual manifestations of fluid retention that, to our knowledge, have not been reported in patients treated with dasatinib. Recognition of these symptoms as a potential complication of dasatinib will help prevent unnecessary investigations, facilitate adequate management, and help alleviate patient anxiety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect